Pending

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
Psoriatic Inflammation Markers Predictive of Response to Adalimumab
Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells
A Study of AK111 in Healthy Subjects
The Maintenance Effect of Enstilar Foam in Combination With Otezla
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
Efficacy of Roflumilast in the Treatment of Psoriasis
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
Development of a Method to Measure mRNA Levels in Skin Samples
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
AMG 827 in Subjects With Psoriatic Arthritis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
Immunologic Response to Secukinumab in Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Diet Interventions in Psoriatic Arthritis
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)
Granulocytapheresis in Psoriasis
Single Cell Genomics of Psoriatic Skin
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
PMCF Study of the A.L.P.S. Proximal Humerus Plating System
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis
Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
Light Treatment Effectiveness (LITE) Study
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Vascular Inflammation in Psoriasis – Apremilast
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Comparison of the Effectiveness of Functional Training Versus Resistance Exercises in Patients With Psoriatic Arthritis
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More wt Group With Moderate/Severe Chronic Plaque Psoriasis
Effects of Tildrakizumab on CFR in Moderate-severe Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
PsA Secukinumab XCT Structural Progression Study
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
A Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.
Tofacitinib for Immune Skin Conditions in Down Syndrome
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Psoriasis Microbiome and Phototherapy
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Dose Tapering Study of Adalimumab in Psoriasis
Assessing Patient Confidence in Biologic Medications
Iontophoresis in Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
Oral Psoriasis Treatment Adherence and Intervention Study
A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
A Safety Study of LY3462817 in Participants With Psoriasis
A Study of LY3471851 in Participants With Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients
Therapeutic Drug Monitoring of Seckinumab in Psoriasis Patients.
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate to Severe Plaque Psoriasis
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
Anakinra for Inflammatory Pustular Skin Diseases
A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
A Phase 4 Clinical Study of Brodalumab
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
Diet Interventions in Psoriatic Arthritis
Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice.
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
Ostraceous Psoriasis Presenting as Koebner Phenomenon in a Tattoo
Nail Psoriasis Treated With Certolizumab Pegol in Patients With Psoriatic Arthritis: Preliminary Observation.
Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis.
The Science and (Lost) Art of Psoralen Plus UVA Phototherapy.
Optimizing Narrowband UVB Phototherapy Regimens for Psoriasis.
How It Works: The Immunology Underlying Phototherapy.
Treatment Strategies Against Psoriasis: Principle, Perspectives And Practices.
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience.
Enhanced anti-psoriatic activity of mycophenolic acid against the TNF-α-induced HaCaT cell proliferation by conjugated poloxamer micelles.
Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis.
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Generalized pustular psoriasis induced by terbinafine.
Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study.
Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis.
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.
Severe Hypocalcemia and Resulting Seizure Caused by Vitamin D Deficiency in an Older Patient Receiving Phenytoin: Eldecalcitol and Maxacalcitol Ointment as Potential Therapeutic Options for Hypocalcemia.
PRURITUS CHARACTERISTICS IN A LARGE ITALIAN COHORT OF PSORIATIC PATIENTS.
Secondary organizing pneumonia (bronchiolitis obliterans with organizing pneumonia) associated with adalimumab for treatment of chronic plaque psoriasis.
Tissue-Resident T Cells: Sequestered immune sensors and effectors of inflammation in Spondyloarthritis.
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy
The Norwegian Drug Monitoring Study
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Dimethyl fumarate dampens IL-17-ACT1-TBK1 axis-mediated phosphorylation of Regnase-1 and suppresses IL-17-induced IκB-ζ expression.
Treatment Adherence and Persistence of Five Commonly Prescribed Medications for Moderate to Severe Psoriasis in a U.S. Commercially Insured Population.
Nail psoriasis treated with intralesional methotrexate infiltration.
Persistence of inflammatory phenotype in residual psoriatic plaques in patients on effective biologic therapy: Residual Psoriatic Plaques After Treatment.
Levocetirizine for the Treatment of Itch in Psoriasis Patients: An Open-label Pilot Study in a Real-world Setting.
Disease burden and patient needs and benefits in anogenital psoriasis: Developmental specificities for person-centred healthcare of emerging adults and adults.
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis.
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study.
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasis.
Effect of narrowband ultraviolet B therapy on serum levels of CD26/dipeptidyl-peptidase IV and truncated forms of substance P in psoriasis patients with pruritus.
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Eczematous eruption after guselkumab treatment for psoriasis.
Inhibition of sphingosine 1phosphate lyase activates human keratinocyte differentiation and attenuates psoriasis in mice.
Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis.
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.
Putting the Patient in Patient-Centred Care: Pilot Testing an Updated Patient Decision Aid for Plaque Psoriasis.
A narrative review of psoriasis and multiple sclerosis: links and risks.
Activation of stem cell up-regulation/mobilization: a cardiovascular risk in both mice and humans with implications for liver disease, psoriasis and SLE.
Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Behçet’s disease with azathioprine.
Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Cytokines Driven Anti-Inflammatory and Anti-Psoriasis Like Efficacies of Nutraceutical Sea Buckthorn (Hippophae rhamnoides) Oil.
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
A Safety Study of LY3462817 in Participants With Psoriasis
Correlation analysis between IL-35, IL-36γ, CCL27 and psoriasis vulgaris.
A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.
Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership.
Psoriasis and risk of malignant lymphoma: a population-based cohort study.
Aloe-emodin: A review of its pharmacology, toxicity, and pharmacokinetics.
Comparing psoriasis advertisement methods with patient willingness to initiate treatment.
A Systematic Review of Treatment Strategies for Erythrodermic Psoriasis.
Failure rates and survival times of systemic and biologic therapies in treating psoriasis: a retrospective study.
Hypoxia inhibits TNF-α-induced TSLP expression in keratinocytes.
Longterm use of fumaric acid esters for the treatment of psoriasis in daily practice.
Huang-Lian-Jie-Du extract ameliorates atopic dermatitis-like skin lesions induced by 2,4-dinitrobenzene in mice via suppression of MAPKs and NF-κB pathways.
Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis.
Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis.
D-Pinitol Ameliorates Imiquimod-Induced PsoriasisLike Skin Inflammation in a Mouse Model via the NF-κB Pathway.
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Risk of fragility fracture among patients with late-onset psoriasis: a UK population-based study.
Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature.
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells.
Secukinumab for patients with plaque psoriasis affected by multiple sclerosis. A mini-review with a representative case report.
Persistence with biological drugs in psoriasis patients followed in dermatology practices in Germany: A retrospective cohort study of 1,201 patients .
Homocysteine and Psoriasis.
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis.
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi’s Varicelliform Eruption.
Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience.
Ayurvedic Treatment Package in Plaque Psoriasis
A Phase 3 Clinical Study of KHK 4827

Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis.
Clinical and Diagnostic Considerations for Atypical, Adult Onset Presentation of Chronic Recurrent Multifocal Osteomyelitis (CRMO).
Dermatology nurses view on factors related to Danish psoriasis patients’ adherence to topical drugs: A focus group study.
Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis.
Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy.
Evaluation of changes in expression pattern of oxidative stress genes under the influence of adalimumab.
Recent Patents Containing Permeation Enhancers for Nail Delivery.
Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children.
Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis.
Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology.
LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8.
A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.
Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases.
Optimal concentration range of ustekinumab in patients with plaque-type psoriasis.
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.
TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
Hyaluronic Acid Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis.
Penta-O-galloyl-β-D-glucose from Paeonia lactiflora Pall. root extract enhances the expression of skin barrier genes via EGR3.
Skin Patterning in Psoriasis by Spatial Interactions between Pathogenic Cytokines.
Oral-Gut Microbiota and Arthritis: Is There an Evidence-Based Axis?
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren’s syndrome.
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn’s Disease
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up.
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
IL-23 inhibitors for moderate-to-severe psoriasis.
The effects of cultural background on patient-perceived impact of psoriatic arthritis – a qualitative study conducted in Brazil and France.
Impact of Decision-Framing in Psoriasis
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.
Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics.
Psoriasis and pregnancy in the biologic era, a feared scenario. What do we do now?
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.
Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study.
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
A modern approach to the treatment of plaque psoriasis.
Ustekinumab treatment for hidradenitis suppurativa.
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt ‒ Identification of a Potent, Selective Series with Biologic-Like In Vivo Efficacy.
Application of medicinal plants in several dermatovenerological entities.
Assessing the Readability of Online Resources for Psoriasis Treatment.
Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis.
Evaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapy.
Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to clinical practice.
Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review.
Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments.
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
Dermatological complications of therapy with biologics in inflammatory autoimmune diseases.
EVALUATION OF PSORIASIS TREATMENT WITH ESOMEPRAZOLE – A PILOT STUDY.
Dapsone-induced hepatic complications: it’s time to think beyond methemoglobinemia.
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.
IL-17A contributes to propagation of inflammation but does not impair adipogenesis and/or insulin response, in adipose tissue of obese individuals.
Secukinumab for patients failing previous TNFα-inhibitor therapy: results of a randomised open-label study (Signature).
The Role of Ultrasound in Assessing Hand Joints and Tendons in Psoriatic Arthritis.
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis.
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Chronotherapy of maxacalcitol on skin inflammation induced by topical 12-O-tetradecanoylphorbol-13-acetate in mice.
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Molecular Targets of Phytochemicals for Skin Inflammation.
[Treatment of psoriasis via lifestyle changes].
Resolvin E1 attenuates murine psoriatic dermatitis.
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum].
Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK Web-based survey.
Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis
Psoriasis patient preferences for topical drugs: a systematic review.
Skin changes in the obese patient.
Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment.
Biological therapy for pustular psoriasis: a systematic review.
Construction of a lncRNA-miRNA-mRNA network to determine the regulatory roles of lncRNAs in psoriasis.
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
Secukinumab for Psoriasis in a Patient With Familial Mediterranean Fever.
Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
A review for the anti-inflammatory effects of paeoniflorin in inflammatory disorders.
Proactive treatment in childhood psoriasis.
Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.

Anti IL-17 in psoriasis.
Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Treatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.
[Molecular diagnostics of hand eczema].
Comorbidities in Patients with Psoriasis.
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
Nanodermatology-Based Solutions for Psoriasis: State-of-the Art and Future Prospects.
Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children.
Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
A Phase II Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Duobrii in Combination With Biologics
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
A Study of LY3471851 in Participants With Psoriasis
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target.
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
Pilot Study of Chinese Medicine Medicated Bath as Complementary Medicine for Mild to Moderate Plaque -Type Psoriasis Patient
Real-world experiences of apremilast in clinics for Japanese patients with psoriasis.
Reasons for diagnostic delays of axial spondyloarthritis.
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Psoriatic arthritis.
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Transungual Excision of Glomus Tumors: A Treatment and Quality of Life Study.
Nanomedicines to Treat Skin Pathologies with Natural Molecules.
Socioeconomic Barriers in the Treatment of Psoriasis.
The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
[Treatment of psoriatic arthritis : Are there differential indications?]
Insights into IL-29: Emerging role in inflammatory autoimmune diseases.
Risankizumab in moderate-to-severe plaque psoriasis.
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation.
Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Advances in phototherapy for psoriasis and atopic dermatitis.
Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression.
Measuring outcomes in psoriatic arthritis: comparing Routine Assessment of Patient Index Data (RAPID3) and Psoriatic Arthritis Impact of Disease (PSAID).
[Esculentoside reduces expression of Th17 cell-related cytokines in the imiquimod-induced psoriasis-like dermatitis mouse model].
Paradoxical psoriasis induced by Tnf-α blockade shows immunological features typical of the early phase of psoriasis development.
One drug and two diseases: a case of multi-drug-resistant Hidradenitis Suppurativa and Psoriasis treated with apremilast.
The Role of Host Defense Peptide Human β-defensins in the Maintenance of Skin Barriers.
Efficacy of methotrexate in management of peripheral psoriatic arthritis – a systematic review.
Effects of non-surgical periodontal therapy on inflammatory markers of psoriasis: A randomized controlled trial.
Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis.
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis.
Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report.
Use of topical calcipotriol for identification of patients with psoriasis in administrative healthcare data – a validation study.
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
Psoriatic Arthritis D2P Screening
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic.
Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial.
Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
Tattoo complications in treated and non-treated psoriatic patients.
Real-World Comparative Effectiveness of Adalimumab, Etanercept, and Methotrexate: A Swedish Register Analysis.
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA)
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Nitidine chloride induces S phase cell cycle arrest and mitochondria-dependent apoptosis in HaCaT cells and ameliorates skin lesions in psoriasis-like mouse models.
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.
Linkage between patients’ characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry.
Could psoralen plus ultraviolet A1 (“PUVA1”) work? Depth penetration achieved by phototherapy lamps.
Achievement of the National Psoriasis Foundation Treatment Targets With Ixekizumab: Pooled Analyses From Four Clinical Studies.
Real-world single-center experience with ten cases of generalized pustular psoriasis successfully treated with ixekizumab.
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM).
Inhibition of Neutrophil Elastase and Cathepsin G As a New Approach to the Treatment of Psoriasis: From Fundamental Biology to Development of New Target-Specific Drugs.
[Health care of chronic inflammatory skin diseases : Do affected individuals seek dermatological care?]
Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
Psoriasis-Arthritis & Bone Program
Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
FGF-7 facilitates the process of psoriasis by inducing TNF-α expression in HaCaT cells.
[Angina pectoris in a 47-year-old athletic man with psoriasis vulgaris].
Evaluation of Galectin3 Levels In Psoriatic Patients treated by narrow-band UVB phototherapy.
Relationship between the efficacy of biologics and clinical plaque psoriasis subtypes in Japanese patients: A single-center pilot study.
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study.
Differences in Wage Earnings between Psoriasis Patients on Biologics versus Those on Oral Therapies: A Population-Based Study in the United States.
Review of IL-17 inhibitors for psoriasis.
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
A 67-Year-Old Man With Psoriatic Arthritis and New-Onset Dyspnea.
Retinoids as an Immunity-modulator in Dermatology Disorders.
A review of topical corticosteroid sprays for the treatment of inflammatory dermatoses.
Tildrakizumab in the treatment of psoriasis – literature review.
Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
A systematic review of diagnostic criteria for psoriasis in adults and children: evidence from studies with a primary aim to develop or validate diagnostic criteria.

Cognitive impairment in patients with psoriasis: A matched case-control study.
Epitope Spreading Phenomenon: A Case Report.
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.
Teledermatology management of difficult-to-treat dermatoses in the Faroe Islands.
Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis.
An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12.
Tridimensional Matryoshka Tattoo: An Important.
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.
Management of TNF inhibitor-induced pulmonary sarcoidosis-like reaction with secukinumab in a psoriasis patient.
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study.
Smart Identification of Psoriasis by Images Using Convolutional Neural Networks: A Case Study in China.
Kan-Lu-Hsiao-Tu-Tan, a traditional Chinese medicine formula, inhibits human neutrophil activation and ameliorates imiquimod-induced psoriasis-like skin inflammation.
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2.
Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis
Concomitant Interstitial Lung Disease with Psoriasis.
Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis.
TNF-alpha inhibition could reduce biomarkers of endothelial dysfunction in patients with moderate to severe psoriasis: A 52-week echo-Doppler based quasi-experimental study.
Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling.
Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.
Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease.
Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients.
Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in-vitro and ex-vivo studies of complex nanoformulation.
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Systematic Review of the Effects of Ultraviolet Radiation on Markers of Metabolic Dysfunction.
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
Ceramide- and Keratolytic-containing Body Cleanser and Cream Application in Patients with Psoriasis: Outcomes from a Consumer Usage Study.
Musa acuminata and its bioactive metabolite 5-Hydroxymethylfurfural mitigates quorum sensing (las and rhl) mediated biofilm and virulence production of nosocomial pathogen Pseudomonas aeruginosa in vitro.
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
Relationships between abstract features and methodological quality explained variations of social media activity derived from systematic reviews about psoriasis interventions.
Self-care for older people with psoriasis.
Bariatric Surgery in Obese Patients With Psoriasis and COPD: Killing Three Birds With One Stone?
Effectiveness comparisons of traditional Chinese medicine for psoriasis: A Bayesian network meta-analysis.
End-to-end test and MOSFET in vivo skin dosimetry for 192Ir high-dose-rate brachytherapy of chronic psoriasis.
An Uncommon Presentation of Erythrodermic Psoriasis in a Patient Without a History of Psoriasis.
Efficacy of long pulsed ND-yag laser in the treatment of nail psoriasis: A clinical and dermoscopic evaluation.
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
New insights into different adipokines in linking the pathophysiology of obesity and psoriasis.
The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors.
Use of the hCONSORT criteria as a reporting standard for herbal interventions for common dermatoses: a systematic review.
Psoriasis localized to the glans penis in a 37-year-old man.
What’s new in topical treatments for psoriasis.
Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis.
A Clinico-Epidemiological Study of Scalp Hair Loss in Children (0-18 Years) in Kota Region, South-East Rajasthan.
Phototherapy achieves significant cost savings by the delay of drug based treatment in psoriasis.
Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
Late-onset psoriasis: diagnosis, assessment and management.
Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis: Results From the NutriNet-Santé Cohort.
Treatment decisions in psoriasis.
Oral psoriasis and SIBO: is there a link?
Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses.
An Open-Label Study to Assess Safety
Meta-analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review.
Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis in BALB/c mice via downregulating NF-κB signaling pathway.
Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience.
Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
Secukinumab for treatment of nail psoriasis: results from the TRANSFIGURE trial.
Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis and Lupus erythematosus.
Does systemic treatment of psoriasis reduce the risk of comorbidities?
Isolation of five Enterobacteriaceae species harbouring blaNDM-1 and mcr-1 plasmids from a single paediatric patient.
DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.
Dimethyl fumarate suppresses hepatocellular carcinoma progression via activating SOCS3/JAK1/STAT3 signaling pathway.
Home phototherapy: experience of setting up a new service in the U.K.’s National Health Service.
Acrodermatitis continua of Hallopeau: clinical perspectives.
Risk Factors for the Development of Psoriasis.
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Cutaneous delivery of [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol, an indole-3-carbinol derivative, mitigates psoriasiform lesion by blocking MAPK/NF-κB/AP-1 activation.
Psoriasis.
Development Of Topical Gel Of Methotrexate Incorporated Ethosomes And Salicylic Acid For Treatment Of Psoriasis.
Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
An update on generalized pustular psoriasis.
Weight Change in Patients with Psoriasis using Tumor Necrosis Factor-Alpha Inhibitors.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments, and switching from etanercept: results from phase 3 studies.
Optimizing preconception care in patients on biologics; MMR vaccination status.
Therapeutic Drug Monitoring of Seckinumab in Psoriasis Patients.
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients
Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician.
Telmisartan Lowers Elevated Blood Pressure in Psoriatic Mice without Attenuating Vascular Dysfunction and Inflammation.
Possible Uses of Plants of the Genus Asphodelus in Oral Medicine.
Severe Acne and Metabolic Syndrome: A Possible Correlation.
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
Ixekizumab Sustains High Level of Efficacy and Favorable Safety Profile Over 4 Years in Patients With Moderate Psoriasis: Results From UNCOVER-3 Study.
Assessing Patient Confidence in Biologic Medications
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy.
ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.
Autonomies in Interaction: Dimensions of Patient Autonomy and Non-adherence to Treatment.
Fournier’s gangrene: Review of 36 cases.
Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice.
A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab.

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy.
Outcomes of Prolonged and Low-dose Ciclosporin in an Asian Population.
Dosage adjustments in patients with psoriasis on adalimumab – a retrospective chart review.
Alexithymia and psoriasis: what is the link?
Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study.
Protocol for a case-control diagnostic accuracy study to develop diagnostic criteria for psoriasis in children (DIPSOC study): a multicentre study recruiting in UK paediatric dermatology clinics.
Risankizumab in the treatment of psoriasis – literature review.
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study.
The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.
Chronic myeloid leukemia in a patient with psoriasis following bimolane treatment.
Systematic Review on Rapidity of Onset of Action for Interleukin-17 and Interleukin-23 Inhibitors for Psoriasis.
Novel findings from determination of common expressed plasma exosomal microRNAs in patients with psoriatic arthritis, psoriasis vulgaris, rheumatoid arthritis, and gouty arthritis.
Superoxide dismutase 3 inhibits LL-37/KLK-5-mediated skin inflammation through modulation of EGFR and associated inflammatory cascades.
Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
An Evaluation of Psoriasis Patient Perceptions and Understanding of Biosimilars: A Canadian Survey Comparing Biologic and Nonbiologic Users.
Human IL-23R Cytokine-Binding Homology Region-Fc Fusion Protein Ameliorates Psoriasis via the Decrease of Systemic Th17 and ILC3 Cell Responses.
Risankizumab for the treatment of psoriasis.
Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review.
Next-Generation Sequencing Technologies for Early-Stage Cutaneous T-Cell Lymphoma.
Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models.
A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome.
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast.
Utility of Repeat Latent Tuberculosis Testing with QuantiFERON-TB Gold test in Psoriasis Patients Treated with TNF-α inhibitors at a Single U.S. Institution.
A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis.
Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
Collaborative Connected Health (CCH) for PCORI
Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial
Steroid-sparing effects and acceptability of a new skin gel containing the anti-inflammatory medicinal substance-nicotinamide.
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.
Recalcitrant infantile generalized pustular psoriasis successfully treated with acitretin and narrowband ultraviolet B.
The effect of botulinum neurotoxin A in patients with plaque psoriasis – an exploratory trial.
Psoriasis verrucosa complicated by generalized pustular psoriasis.
Case of generalized pustular psoriasis that might have progressed from terbinafine-induced acute generalized exanthematous pustulosis.
Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.
Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy.
C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis.
Serum active 1,25(OH)2D, but not inactive 25(OH)D vitamin D levels are associated with cardiometabolic and cardiovascular disease risk in psoriasis.
Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab.
Artesunate alleviates imiquimod-induced psoriasis-like dermatitis in BALB/c mice.
Derailed Ceramide Metabolism in Atopic Dermatitis (AD): A Causal Starting Point for a Personalized (Basic) Therapy.
Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
Semaphorin3A is a promising therapeutic tool for bronchial asthma.
A retrospective review of dupilumab and psoriasis biologic combination therapy.
Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.
Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia.
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1.
Google search trends in psoriasis: a pilot evaluation of global population interests.
Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.
Dietary compounds as potential modulators of microRNA expression in psoriasis.
Exploring the illness representations of people with psoriatic arthritis: a secondary analysis of focus group data.
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil.
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis
Yoga-mindfulness for Chronic Arthritis Patients With Persistent Pain – a Pragmatic Randomized Controlled Trial
PMCF Study of the A.L.P.S. Proximal Humerus Plating System
Psoriasis patients’ preference for an aerosol foam topical formulation.
Psoriasis cases of same diagnosis but different phenotypes-Management through individualized homeopathic therapy.
308nm Excimer Laser for Treatment of Fingernail Psoriasis
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab.
Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN.
Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples.
Developing an online patient education resource for topical therapy: a pilot study.
Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris.
Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis.
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.
Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis – a simplified dosing regimen at the expense of efficacy?
Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam.
Misuse of traditional Chinese medicine may be a risk factor to tumorigenesis and progression of head and neck carcinoma in China: a hypothesis based on a case series.
Severe childhood psoriasis: need for safety and efficacy data on long-term treatment with biologics.
Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry
Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
A Review of Topical Corticosteroid Foams
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab
The Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept
Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council.
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Therapeutic Targeting of the IGF Axis.
New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus.
Diagnosis and screening of patients with generalized pustular psoriasis.
How Do We Treat Psoriasis Patients with Hepatitis C Infections in Real-World Situations? A Retrospective Analysis of 34 Patients.
Efficacy and safety of HAT1 compared to calcipotriol in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results from an open-label randomized comparative pilot clinical study.
Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
Therapeutic inertia in the management of moderate to severe plaque psoriasis.
Developement, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model.
Users of Biologics in Clinical Practice: would they be eligible for Phase III Clinical Studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
[Virtual screening study of cathepsin S natural inhibitor].
Herpes simplex virus encephalitis in a patient receiving ustekinumab associated with extensive cerebral oedema and brainshift successfully treated by immunosuppression with dexamethasone.
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Triptolide prevents osteoarthritis via inhibiting hsa-miR-20b.

Investigation of psoriasis skin tissue by label-free multi-modal imaging: a case study on a phototherapy-treated patient.
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy
Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective.
Pediatric case of generalized pustular psoriasis developing acute pancreatitis.
Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis.
Terbinafine-induced generalized pustular psoriasis in a patient carrying CARD14 mutation.
Switching biologics in the treatment of psoriatic arthritis in Japan.
5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatitis probably through inhibition of IL-17A production and keratinocyte activation.
The Effect of Calcipotriene-Betamethasone Dipropionate Aerosol Foam versus Vehicle on Target Lesions in Moderate Severity Plaque Psoriasis: Focus on Elbows and Knees
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present).
The Role of IL-17 in Papulopustular Rosacea and Future Directions.
Incidence of Cardiovascular Events Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Pooled Data from 3 Large Randomised Clinical Trials.
Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.
Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation.
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
Oral Psoriasis Treatment Adherence and Intervention Study
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Chlorin, Phthalocyanine, and Porphyrin Types Derivatives in Phototreatment of Cutaneous Manifestations: A Review.
APOBEC3 regulates keratinocyte differentiation and expression of Notch3.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis.
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.
Clinical and metabolic analysis of disorders in psoriatic patients.
Evans Syndrome in Childhood: Long Term Follow-Up and the Evolution in Primary Immunodeficiency or Rheumatological Disease.
Inhibitory effect of α-amyrin acetate isolated from Fraxinus rhynchophylla on Th17 polarization.
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Clinical Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Guselkumab for the treatment of psoriasis – evidence to date.
Is the concept of clinical equipoise maintained in psoriasis research?
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Rapid debridement with monofilament fibre debridement technology: clinical outcomes and practitioner satisfaction.
Judicial precedents on medicolegal disputes arising from psoriasis treatment in South Korea.
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
Guselkumab in the Treatment of Concomitant Hidradenitis Suppurativa, Psoriasis, and Crohn’s Disease.
Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment.
Effect of white mange mixture in a murine model of psoriasis.
Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report.
Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports.
Biosimilars in dermatology: The wind of change.
Immunologic adverse reactions of β-blockers and the skin.
Association of aortic vascular uptake of 18FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study.
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Risankizumab (Skyrizi) for psoriasis.
Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study.
Subcutaneous Methotrexate versus oral form for treatment and prophylaxis of chronic plaque Psoriasis.
Drugs for psoriasis.
A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.
Chronic nonbacterial osteomyelitis in children: a multicenter case series.
Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin.
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review.
A rare case of brucellosis with dermatomal pattern of cutaneous manifestation.
Interleukin-17A affects extracellular vesicles release and cargo in human keratinocytes.
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.
A comprehensive review of rituximab therapy in rheumatoid arthritis patients.
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
How Biotin Induces Misleading Results in Thyroid Bioassays: Case Series.
[Insufficient tetanus vaccination protection in psoriasis and systemic immunosuppression : Results of a retrospective investigation of 101 patients].
A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report.
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index.
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
Erianin Inhibits Proliferation and Induces Apoptosis of HaCaT Cells via ROS-Mediated JNK/c-Jun and AKT/mTOR Signaling Pathways.
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.
Sarcoid- like Phenomenon – ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature.
Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis.
[Spectrum of psoriatic conditions].
Clinical considerations for the management of psoriasis in women.
Encapsulation and controlled release of retinol from silicone particles for topical delivery.
[No increased risk of severe infections under biologic therapies in psoriasis].
Psoriasis and Depression: The Role of Inflammation.
Ferulic acid altered IL-17A/IL-17RA interaction and protected against imiquimod-induced psoriasis-like skin injury in mice.
Obesity in psoriatic arthritis: Comparative prevalence and associated factors.
Predicting treatment success with biologics in psoriasis.
α-Amylase inhibition of xanthones from Garcinia mangostana pericarps and their possible use for the treatment of diabetes with molecular docking studies.
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis.
Total glucosides of paeony attenuates animal psoriasis induced inflammatory response through inhibiting STAT1 and STAT3 phosphorylation.
Etanercept (Enbrel®) in Psoriasis – Pediatrics
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.
Adalimumab – Safe and Effective Therapy for an Adolescent Patient with Severe Psoriasis and Immune Thrombocytopenia.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.
Thalidomide-induced psoriasis in a patient with multiple myeloma.
Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Treatment consideration for US military members with skin disease.
Novel antipsoriatic fluidized spanlastic nanovesicles: in vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy.
Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.
Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
Adalimumab- Induced Scalp Psoriasis with Severe Alopecia.
Haut-Tief Patient Education on Psoriasis and Eczema
The Effect of Vitamin D Supplementation on Psoriasis Severity
The HLA-Cw12 Allele Is an Important Susceptibility Allele for Psoriasis and Is Associated with Resistant Psoriasis in the Turkish Population.
PsA Secukinumab XCT Structural Progression Study
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis

Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment
Evaluating nail thickness and stiffness with shear-wave elastography in nail psoriasis: A preliminary study.
A Closer Look at the Data Regarding Suicidal Ideation and Behavior in Psoriasis Patients: The Case of Brodalumab
Assessing Efficacy and the Speed of Response in Psoriasis Treatment.
StatPearls
StatPearls
Intracranial hypertension syndrome in a patient with psoriasis receiving ustekinumab.
Treatment Appraisal Reports: Usefulness and Transparency.
Acute onset of psoriatic spondyloarthritis as a new manifestation of post-streptococcal reactive arthritis: a case series.
Nonclinical Safety and Toxicokinetics of MnTE-2-PyP (BMX-010), a Topical Agent in Phase 2 Trials for Psoriasis and Atopic Dermatitis.
Assessment of the Possible Role of FOXP3 Gene (rs3761548) Polymorphism in Psoriasis Vulgaris Susceptibility and Pathogenesis: Egyptian Study.
A Survey of Treatment Practices in Management of Psoriasis Patients among Dermatologists of Kerala.
Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study.
Dose Tapering Study of Adalimumab in Psoriasis
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencing.
Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink.
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn’s disease?
Current views on metabolic syndrome.
Paracetamol-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient under apremilast therapy.
Prescription-based prevalence of biological therapy in patients with psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.
[Advances in research of bispecific antibodies for antivirus therapy].
The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, IL17 in patients with psoriasis and in a control.
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U trial).
Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin.
Complete Skin Clearance and PASI response rates in clinical practice- Predictors, Health Related Quality of Life improvements and implications for treatment goals.
Severe psoriasis entering remission after treatment for latent tuberculosis with isoniazid: Report of two cases.
Adalimumab use in patients with psoriasis and hepatitis B: a case series.
Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.
Depression and suicidality in psoriasis patients: emotional needs to discover.
Withanolides, Extracted from Datura Metel L. Inhibit Keratinocyte Proliferation and Imiquimod-Induced Psoriasis-Like Dermatitis via the STAT3/P38/ERK1/2 Pathway.
Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
[THE ROLE OF VITAMIN D IN THE DEVELOPMENT OF PSORIASIS AND ACNE].
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study.
A Case of Severe Symptomatic Central Nervous System Sarcoidosis Secondary to Treatment with Adalimumab.
How do you determine the optimal biologic treatment for psoriasis?
Furocoumarins as multi-target agents in the treatment of cystic fibrosis.
FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis
Psoriasis Microbiome and Phototherapy
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
Genital Psoriasis: Impact on Quality of Life and Treatment Options.
The pathological role of Wnt5a in psoriasis and psoriatic arthritis.
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
Generalized pustular psoriasis: A possible association with severe hypocalcaemia due to primary hypoparathyroidism.
Apremilast for a psoriasis patient with HIV and hepatitis C.
Acquired hemophilia A following generalized pustular psoriasis of pregnancy.
Therapeutic drug monitoring of biologics in psoriasis.
Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis.
Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris.
Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?
Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.
Lifestyle changes for treating psoriasis.
The Efficacy of UVA1 Phototherapy in Psoriasis: Clinical and Histological Aspects.
Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting.
A Study on the Association of Psoriasis with Metabolic Disorders.
Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
Stepping Up For Inflammatory Arthritis
Topical corticosteroids application in the evening is more effective than in the morning in psoriasis: results of a prospective comparative study.
DMARDs in psoriasis: a critical appraisal.
Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis.
The Incidence Rates and Risk Factors of Parkinson’s Disease in Patients with Psoriasis: A Nationwide Population-based Cohort Study.
Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks from a Phase-3, Randomized, Placebo-Controlled Trial.
Treatment patterns in UK adult patients with atopic dermatitis treated with systemic immunosuppressants: data from The Health Improvement Network (THIN).
Timing of quality of life improvements in psoriatic patients treated with different systemic therapies.
Development and Characterization of a Potent Tumor Necrosis Factor-Alpha-Blocking Agent.
Natural Language Processing of Reddit Data to Evaluate Dermatology Patient Experiences and Therapeutics.
Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity.
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course.
Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials.
Anti-inflammatory effect of naringin and sericin combination on human peripheral blood mononuclear cells (hPBMCs) from patient with psoriasis.
Down-regulation of tissue levels of serine protease inhibitor (vaspin) in psoriasis vulgaris patients: a possible mechanism of narrowband ultraviolet B radiation.
Pruritus in Autoimmune and Inflammatory Dermatoses.
Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis.
The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Occult HIV infection in Japanese rupioid psoriasis.
Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis.
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis
The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.
Close correlation of bone mineral density and body mass index in Japanese psoriasis patients.
Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.
Renal failure in dogs kept by a man with severe psoriasis.
Soccer helps in controlling the development of psoriasis in Italian second league players.
Efficiency and safety of a Curcuma extract combined with visible blue light phototherapy on adults with plaque psoriasis: A phase IV, randomized, open pilot clinical trial.
Prevalence and current therapies of psoriatic arthritis in Japan: A survey by the Japanese Society of Psoriasis Research in 2016.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis.
Pathogenetic Therapy of Psoriasis by Muramyl Peptide.
Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases.
Differential microRNA expression profile in the plasma of preeclampsia and normal pregnancies.
Effects of Infliximab against Methotrexate Toxicity in Splenic Tissue via the Regulation of CD3, CD68, and C200R in Rats.
A real-life experience of psoriatic patients with history of cancer treated with biological drugs.
Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin.
Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab.

Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab.
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society).
Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents.
Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence.
Response to IL17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL17A gene: results from a multicentre study of four European psoriasis cohorts.
Safety and Efficacy of Fecal Microbiota Transplantation
Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis
MAP Study: Methotrexate and Adalimumab in Psoriasis
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis
Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial.
Exopolysaccharides from Cyanobacterium aponinum induce a regulatory dendritic cell phenotype and inhibit SYK and CLEC7A expression in dendritic cells, T cells and keratinocytes.
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Comparable Efficacy and Safety of Brodalumab in Obese and Non-Obese Patients With Psoriasis: Analysis of 2 Randomized Controlled Trials.
PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Case of recalcitrant nail psoriasis unresponsive to adalimumab but successfully treated with infliximab.
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience.
Pharmacotherapeutic management of psoriasis in adolescents and children.
C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis.
Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease.
Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus.
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Safety and Efficacy of Secukinumab in Mild Psoriasis
New biologics in psoriasis – progress and problems.
Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells.
Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body.
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Patients’ knowledge about psoriasis and comorbidities; their participation in treatment decisions.
Photodynamic Therapy of Psoriasis Using Photosensitizers of Vegetable Origin.
Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report.
Carbenoxolone ameliorates hepatic lipid metabolism and inflammation in obese mice induced by high fat diet via regulating the JAK2/STAT3 signaling pathway.
Moderate to Severe Psoriasis in Childhood and Adolescence: A Therapeutic Challenge.
The Importance of Measuring the Psychological Impact of Psoriasis and How We Treat Pediatric Patients With Psoriasis.
Phototherapy for psoriasis – outdated or underused?
Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies.
The IL-23/IL-17 pathway in human chronic inflammatory diseases – new insight from genetics and targeted therapies.
The Psoriasis Therapeutic Potential of a Novel Short Laminin Peptide C16.
Potential Therapeutic Applications of Bee Venom on Skin Disease and Its Mechanisms: A Literature Review.
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Roles of circular RNAs in immune regulation and autoimmune diseases.
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials.
Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient.
Bacteriophage of the Skin Microbiome in Patients with Psoriasis and Healthy Family Controls.
Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment
Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk.
General survey of Fructus Psoraleae from the different origins and chemical identification of the roasted from raw Fructus Psoraleae.
La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos.
The role of PI3K/AKT/FOXO signaling in psoriasis.
[Psoriasis: Initial assessment and practical therapy evaluation].
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Biosimilars for the treatment of psoriasis.
[Anti-TNF biosimilars in psoriasis treatment].
Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
Study of Secukinumab With 2 mL Pre-filled Syringes
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
A Clinical Trial of Tildrakizumab in Pediatric Subjects With Moderate to Severe Chronic Plaque Psoriasis
VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn’s disease, rheumatoid arthritis or psoriasis treated in clinical practice in New Zealand.
Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus.
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
Systemic effects of IL-17 in inflammatory arthritis.
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council.
Secukinumab treatment does not alter the pharmacokinetics of the CYP3A4 substrate midazolam in patients with moderate to severe psoriasis.
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study.
MicroRNA expression, targeting, release dynamics and early-warning biomarkers in acute cardiotoxicity induced by triptolide in rats.
Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
Occurrence and challenges in the management of severe chronic plaque type psoriasis in a limited resourced setting: a case report.
Management of psoriasis as a systemic disease: What is the evidence?
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
[Psoriasis therapy in pregnancy : Consultation of pregnant patients].
Item 114 – UE 4 Psoriasis.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
Evaluation of serum folate level before and after Bath PUVA therapy in patients referred to Razi hospital, Rasht, Iran.
Interleukin-17: Functional and Structural Features, Application as a Therapeutic Target.
Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective.
A case of guttate psoriasis during treatment with dupilumab.
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial.
Assessment of cardiac and vessel functions in childhood psoriasis
[French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults].
Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission.
Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study.
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
Nanostructured supramolecular hydrogels: Towards the topical treatment of Psoriasis and other skin diseases.
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis